11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration.

      Cancer research
      ADAM Proteins, genetics, immunology, metabolism, Breast Neoplasms, pathology, Cell Line, Tumor, Cell Membrane, enzymology, Cell Movement, physiology, Cross Reactions, DNA Primers, Disease Progression, Female, Gene Expression Regulation, Enzymologic, Humans, Immunoblotting, Isoenzymes, Membrane Proteins, Mutation, RNA, Small Interfering, Sequence Deletion, Transfection

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tumor cell migration is mediated by cell-autonomous signaling mechanisms as well as paracrine and autocrine factors secreted by activated stromal cells in the tumor microenvironment. Like other members of the ADAM (a disintegrin and metalloproteinase) family, the integrin-binding metalloproteinase ADAM9 modulates cell-cell and cell-matrix interactions as well as ectodomain shedding of cell surface receptors and ligands, thereby modifying intracellular and extracellular signaling. ADAM9 transcripts are alternatively spliced to express a transmembrane protein (ADAM9-L) and a secreted variant (ADAM9-S). In this study, we show that ADAM9-S promotes breast cancer cell migration in a manner requiring its metalloproteinase activity, whereas ADAM9-L suppresses cell migration independent of its metalloproteinase activity. Suppression of migration by ADAM9-L requires a functional disintegrin domain and integrin binding. Expression analysis revealed that both ADAM9 isoforms are expressed in breast cancer cell lines and tissues. Therefore, relative levels of membrane-tethered and secreted variants of ADAM9 are a key determinant in manifestation of aggressive migratory phenotypes associated with breast cancer progression. ©2010 AACR.

          Related collections

          Author and article information

          Comments

          Comment on this article